FDA: blood clot, death risk up with higher dose of tofacitinib

New warnings about an increased risk of thrombosis and of death among ulcerative colitis patients taking the 10 mg twice daily dose of the drug tofacitinib (Xeljanz, Xeljanz XR) have been issued by the U.S. Food and Drug Administration.

source https://www.lifetechnology.com/blogs/life-technology-news-blog/fda-blood-clot-death-risk-up-with-higher-dose-of-tofacitinib